Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: Nat Biotechnol. 2013 Feb 10;31(3):213–219. doi: 10.1038/nbt.2514

Table 2.

Published validation rates in coding regions

Tumor type Mutation rate / Mb (** non-silent) Validation technology Validated Invalidated Validation rate False positive rate / Mb
Multiple Myeloma19 2.9 Sequenom 87 5 94.6% 0.16
Head and Neck 4 3.3 Sequenom 181 8 95.8% 0.14
Breast3 2.9 Sequenom/PCR/45 464 27 94.5% 0.16
Prostate24 1.4 Sequenom 219 10 95.6% 0.06
Colorectal25 5.9 Sequenom 292 16 94.8% 0.31
CLL26 0.9 Sequenom 66 5 93.0% 0.06
Medulloblastoma27 0.4** Fluidigm/PacBio 19 0 100.0% n/a (5 genes)
Prostate28 0.9 Sequenom 253 26 90.7% 0.08
DLBCL29 3.2** Fluidigm/Illumina 46 1 97.9% n/a (6 genes)
TCGA Colorectal7 14 PCR/454 5,713 420 93.1% 0.96
Lung Adeno30 12 Capture/Illumina 9,458 374 96.2% 0.46